Myovant Sciences Ltd. (NYSE:MYOV) and BioLineRx Ltd. (NASDAQ:BLRX) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Myovant Sciences Ltd.||16||0.00||N/A||-4.08||0.00|
Table 1 demonstrates Myovant Sciences Ltd. and BioLineRx Ltd.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 provides us Myovant Sciences Ltd. and BioLineRx Ltd.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Myovant Sciences Ltd.||0.00%||-590.4%||-157%|
The following table delivered below contains the ratings and recommendations for Myovant Sciences Ltd. and BioLineRx Ltd.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Myovant Sciences Ltd.||0||0||1||3.00|
Myovant Sciences Ltd. has a 249.16% upside potential and a consensus price target of $25.
Insider & Institutional Ownership
Roughly 33.4% of Myovant Sciences Ltd. shares are owned by institutional investors while 27.13% of BioLineRx Ltd. are owned by institutional investors. Insiders owned roughly 56.5% of Myovant Sciences Ltd.’s shares. Competitively, insiders own roughly 3.46% of BioLineRx Ltd.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Myovant Sciences Ltd.||-9.21%||-18.18%||-59.09%||-61.14%||-63.47%||-56.12%|
For the past year BioLineRx Ltd. has weaker performance than Myovant Sciences Ltd.
On 4 of the 7 factors BioLineRx Ltd. beats Myovant Sciences Ltd.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and GenentechÂ’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in ModiÂ’in, Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.